Steffen Höring
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Steffen Höring has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Bettina Löffler
Institute of Medical Microbiology, Jena University Hospital, Jena, Germany
3 shared publicationsJürgen Rödel
Institute of Medical Microbiology, Jena University Hospital, Jena, Germany
2 shared publicationsAlain Sami Massarani
Institute of Medical Microbiology, Jena University Hospital, Am Klinikum 1, 07747, Jena, Germany
1 shared publicationB. Löffler
Institute of Medical Microbiology, Jena University Hospital, Jena, Germany
1 shared publicationB. T. Schleenvoigt
Institute for Infectious Diseases and Infection Control, Jena University Hospital, Jena, Germany
1 shared publication- Jürgen Rödel
Institute of Medical Microbiology, Jena University Hospital, Friedrich Schiller University of Jena, Jena, Germany
1 shared publication
Latest Publications
- 10 December 2019
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 39 (4) , 679-688
Diagnostic accuracy and clinical impact of loop-mediated isothermal amplification for rapid detection of Staphylococcus aureus bacteremia: a retrospective observational study
The aim of this study was to evaluate the diagnostic accuracy and the clinical impact of isothermal loop-mediated amplification (LAMP; eazyplex® MRSA kits) for rapid diagnosis of Staphylococcus aureus bacteremia (SAB) in comparison with conventional blood culture diagnostics. We performed a retrospective, single-center observational study over the period between November 2016 and December 2018 on patients (and blood cultures) with growth of Gram-positive cocci in clusters in their blood cultures. We quantified diagnostic accuracy with sensitivity and specificity for detection of S. aureus, methicillin-resistant S. aureus (MRSA), and the mecA/C resistance genes in 797 blood cultures. The clinical impact was assessed by time to result reporting, time to appropriate treatment, and length of stay in intensive care unit (ICU) in 190 SAB patients. We observed sensitivity and specificity above 90% for S. aureus detection (sensitivity (95% confidence interval (CI)), 99.57% (97.61%, 99.98%); specificity, 99.12% (97.95%, 99.71%)), for MRSA detection (sensitivity, 100% (89.11%, 100.00%); specificity, 99.72% (99.05, 99.96)), and for mecA/C detection (sensitivity, 94.71% (91.85%, 96.78%); specificity, 95.89% (93.58%, 97.54%)). LAMP testing was associated with shorter median time to result reporting (24.0 h (first and third quartiles (Q1–Q3), 20.0–27.0 h) vs 41.5 h (36.0–46.0 h); p < 0.001) and different distribution of time to appropriate treatment (2.0 days (1.0–3.0) vs 2.0 days (2.0–3.0); p = 0.004). No evidence for differences in length-of-stay in ICU was observed. Our analysis suggests for the application of LAMP (i) a high diagnostic accuracy for detection of S. aureus and the mecA/C genes in blood cultures, (ii) an earlier result reporting, and (iii) a shorter time to appropriate treatment.
- 10 December 2019
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 39 (4) , 679-688
Diagnostic accuracy and clinical impact of loop-mediated isothermal amplification for rapid detection of Staphylococcus aureus bacteremia: a retrospective observational study
The aim of this study was to evaluate the diagnostic accuracy and the clinical impact of isothermal loop-mediated amplification (LAMP; eazyplex® MRSA kits) for rapid diagnosis of Staphylococcus aureus bacteremia (SAB) in comparison with conventional blood culture diagnostics. We performed a retrospective, single-center observational study over the period between November 2016 and December 2018 on patients (and blood cultures) with growth of Gram-positive cocci in clusters in their blood cultures. We quantified diagnostic accuracy with sensitivity and specificity for detection of S. aureus, methicillin-resistant S. aureus (MRSA), and the mecA/C resistance genes in 797 blood cultures. The clinical impact was assessed by time to result reporting, time to appropriate treatment, and length of stay in intensive care unit (ICU) in 190 SAB patients. We observed sensitivity and specificity above 90% for S. aureus detection (sensitivity (95% confidence interval (CI)), 99.57% (97.61%, 99.98%); specificity, 99.12% (97.95%, 99.71%)), for MRSA detection (sensitivity, 100% (89.11%, 100.00%); specificity, 99.72% (99.05, 99.96)), and for mecA/C detection (sensitivity, 94.71% (91.85%, 96.78%); specificity, 95.89% (93.58%, 97.54%)). LAMP testing was associated with shorter median time to result reporting (24.0 h (first and third quartiles (Q1–Q3), 20.0–27.0 h) vs 41.5 h (36.0–46.0 h); p < 0.001) and different distribution of time to appropriate treatment (2.0 days (1.0–3.0) vs 2.0 days (2.0–3.0); p = 0.004). No evidence for differences in length-of-stay in ICU was observed. Our analysis suggests for the application of LAMP (i) a high diagnostic accuracy for detection of S. aureus and the mecA/C genes in blood cultures, (ii) an earlier result reporting, and (iii) a shorter time to appropriate treatment.
- Open Access
- 1 March 2019
- Published by Microbiology Society in Access Microbiology
- Vol. 1 (1) , e000012
Dwarfs in disguise: multiple spinal abscesses and spondylodiscitis caused by an Enterococcus faecium small-colony variant
Small-colony variants are slow-growing subpopulations of bacteria known to be involved in latent or recurrent infections, especially in deep-seated foci. Their atypical growth in small colonies can hamper prompt and correct identification in clinical specimens. Here, we present the first case of multiple spinal abscesses and spondylodiscitis associated with an Enterococcus faecium small-colony-variant in an immunocompetent patient. This case demonstrates the diagnostic challenges when encountering this phenotype in the diagnostic laboratory.
- 1 March 2019
- Published by Microbiology Society in Access Microbiology
- Vol. 1 (1) , e000012
Open AccessDwarfs in disguise: multiple spinal abscesses and spondylodiscitis caused by an Enterococcus faecium small-colony variant
Small-colony variants are slow-growing subpopulations of bacteria known to be involved in latent or recurrent infections, especially in deep-seated foci. Their atypical growth in small colonies can hamper prompt and correct identification in clinical specimens. Here, we present the first case of multiple spinal abscesses and spondylodiscitis associated with an Enterococcus faecium small-colony-variant in an immunocompetent patient. This case demonstrates the diagnostic challenges when encountering this phenotype in the diagnostic laboratory.
- 24 January 2019
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 38 (3) , 471-478
Rapid antibiotic susceptibility testing in blood culture diagnostics performed by direct inoculation using the VITEK®-2 and BD Phoenix™ platforms
Early availability of microbiological results can improve treatment decisions of patients suffering from bloodstream infections. Direct inoculation of automated susceptibility testing (AST) platforms is an approach to shorten time-to-result in blood culture diagnostics. We performed a comparative evaluation of the two commercial AST systems VITEK®-2 and BD Phoenix™ for the direct inoculation with blood culture samples. Furthermore, two different methods of sample preparation were compared in this study. Positive blood cultures were prepared for direct inoculation by use of serum separator tubes and twofold centrifugation. AST was performed with the VITEK®-2 and the BD Phoenix™ system by the standard method according to the manufacturer’s recommendations using subcultures on solid media and by direct inoculation of blood culture samples. A hundred clinical samples from blood cultures were included in this study. Rapid AST by direct inoculation showed inter-test agreement rates ranging from 92.45 to 97.7%. Comparing both AST platforms, the VITEK®-2 system demonstrated a higher test accuracy for direct inoculation. No relevant difference was observed for the two different sample preparation methods. Direct inoculation is an easy and inexpensive approach to obtain early full panel phenotypic AST results in blood culture diagnostics. Sample preparation is sufficiently performed by a simple centrifugation method. Both commercial platforms, the VITEK®-2 and the BD Phoenix™, have proven suitable for the use of direct inoculation.
- 24 January 2019
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 38 (3) , 471-478
Rapid antibiotic susceptibility testing in blood culture diagnostics performed by direct inoculation using the VITEK®-2 and BD Phoenix™ platforms
Early availability of microbiological results can improve treatment decisions of patients suffering from bloodstream infections. Direct inoculation of automated susceptibility testing (AST) platforms is an approach to shorten time-to-result in blood culture diagnostics. We performed a comparative evaluation of the two commercial AST systems VITEK®-2 and BD Phoenix™ for the direct inoculation with blood culture samples. Furthermore, two different methods of sample preparation were compared in this study. Positive blood cultures were prepared for direct inoculation by use of serum separator tubes and twofold centrifugation. AST was performed with the VITEK®-2 and the BD Phoenix™ system by the standard method according to the manufacturer’s recommendations using subcultures on solid media and by direct inoculation of blood culture samples. A hundred clinical samples from blood cultures were included in this study. Rapid AST by direct inoculation showed inter-test agreement rates ranging from 92.45 to 97.7%. Comparing both AST platforms, the VITEK®-2 system demonstrated a higher test accuracy for direct inoculation. No relevant difference was observed for the two different sample preparation methods. Direct inoculation is an easy and inexpensive approach to obtain early full panel phenotypic AST results in blood culture diagnostics. Sample preparation is sufficiently performed by a simple centrifugation method. Both commercial platforms, the VITEK®-2 and the BD Phoenix™, have proven suitable for the use of direct inoculation.
- 30 June 2018
- Published by Springer Nature in Infection
- Vol. 46 (5) , 599-605
Dual antiretroviral therapy with tenofovir (TDF) and darunavir/ritonavir (DRV/RTV) in an HIV-1 positive patient: a case report, review, and meta-analysis of the literature on dual treatment strategies using protease inhibitors in combination with an NRTI
Here, we report the case of an HIV positive patient under a dual antiretroviral drug regimen with tenofovir disoproxil and darunavir/ritonavir with stable clinical, virological, and immunological response over 126 weeks. Dual antiretroviral therapy has the advantage of reduced toxicity and lower health care costs, treatment failure and fostering drug resistance are perceived risks. Optimal drug combinations and indication criteria for dual treatment remain controversial. Nevertheless, first clinical trials indicate non-inferiority for combinations of nucleoside reverse transcriptase inhibitors and protease inhibitors. This case presents the combination of tenofovir disoproxil in combination with a protease inhibitor as a new potential dual treatment regimen.
- 30 June 2018
- Published by Springer Nature in Infection
- Vol. 46 (5) , 599-605
Dual antiretroviral therapy with tenofovir (TDF) and darunavir/ritonavir (DRV/RTV) in an HIV-1 positive patient: a case report, review, and meta-analysis of the literature on dual treatment strategies using protease inhibitors in combination with an NRTI
Here, we report the case of an HIV positive patient under a dual antiretroviral drug regimen with tenofovir disoproxil and darunavir/ritonavir with stable clinical, virological, and immunological response over 126 weeks. Dual antiretroviral therapy has the advantage of reduced toxicity and lower health care costs, treatment failure and fostering drug resistance are perceived risks. Optimal drug combinations and indication criteria for dual treatment remain controversial. Nevertheless, first clinical trials indicate non-inferiority for combinations of nucleoside reverse transcriptase inhibitors and protease inhibitors. This case presents the combination of tenofovir disoproxil in combination with a protease inhibitor as a new potential dual treatment regimen.